Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anemia 6Colorectal Neoplasms 3Anemia, Iron-Deficiency 3Postoperative Complications 2Neoplasms 2Adenocarcinoma 2Pancreatic Neoplasms 1Lymphoproliferative Disorders 1Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1

Interventions

Cyclophosphamide 20Trastuzumab 12Epirubicin 12Doxorubicin 12Docetaxel 11Paclitaxel 10Filgrastim 8Carboplatin 7Radiotherapy 6Bevacizumab 5Neoadjuvant Therapy 4Lapatinib 4Granulocyte Colony-Stimulating Factor 4Albumin-Bound Paclitaxel 4tipifarnib 3pertuzumab 3pegfilgrastim 3Thiotepa 3Taxes 3Tamoxifen 3Surgical Procedures, Operative 3Melphalan 3Fluorouracil 3Chemotherapy, Adjuvant 3Capecitabine 3130-nm albumin-bound paclitaxel 3Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Inflammatory Breast Neoplasms × ferric carboxymaltose × Clear all
NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡